Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial

NCT03049540 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT03049540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03049540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Phase 3
Overall status
Completed
Start date
October 25, 2017
Completion date
October 28, 2021
Enrollment
100 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

heart defects, congenital, transposition of great vessels with ventricular inversion